Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Advanced or Metastatic Urothelial Cancer
NCT00112671Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2005
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in urothelial carcinoma (UC), sponsored by National Cancer Institute. Started Apr 2005; status: completed.
02
Drugs
sorafenib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00112671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00112671.